Comment on

• Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children.

  Kann BH, Park HS, Lester-Coll NH, Yeboa DN, Benitez V, Khan AJ, Bindra RS, Marks AM, Roberts KB. Kann BH, et al. JAMA Oncol. 2016 Dec 1;2(12):1574-1581. doi: 10.1001/jamaoncol.2016.2547. JAMA Oncol. 2016. PMID: 27491009
• 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

  Ermoian RP, Breneman J, Walterhouse DO, Chi YY, Meza J, Anderson J, Hawkins DS, Hayes-Jordan AA, Parham DM, Yock TI, Donaldson SS, Wolden SL. Ermoian RP, et al. Pediatr Blood Cancer. 2017 Sep;64(9):10.1002/pbc.26540. doi: 10.1002/pbc.26540. Epub 2017 May 26. Pediatr Blood Cancer. 2017. PMID: 28548706 Free PMC article. Clinical Trial.
• Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma.

  Jhawar SR, Rivera-Núñez Z, Drachtman R, Cole PD, Hoppe BS, Parikh RR. Jhawar SR, et al. JAMA Oncol. 2019 May 1;5(5):689-695. doi: 10.1001/jamaoncol.2018.5911. JAMA Oncol. 2019. PMID: 30605220 Free PMC article.
• Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma.

  Merchant TE, Bendel AE, Sabin ND, Burger PC, Shaw DW, Chang E, Wu S, Zhou T, Eisenstat DD, Foreman NK, Fuller CE, Anderson ET, Hukin J, Lau CC, Pollack IF, Laningham FH, Lustig RH, Armstrong FD, Handler MH, Williams-Hughes C, Kessel S, Kocak M, Ellison DW, Ramaswamy V. Merchant TE, et al. J Clin Oncol. 2019 Apr 20;37(12):974-983. doi: 10.1200/JCO.18.01765. Epub 2019 Feb 27. J Clin Oncol. 2019. PMID: 30811284 Free PMC article. Clinical Trial.